Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Change in Accured Expenses (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Change in Accured Expenses for 4 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 56.62% to $1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.5 million, a 10.17% decrease, with the full-year FY2025 number at -$2.5 million, down 10.17% from a year prior.
  • Change in Accured Expenses was $1.8 million for Q4 2025 at Spruce Biosciences, up from $1.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $4.2 million in Q4 2024 to a low of -$6.3 million in Q3 2024.
  • A 4-year average of -$330000.0 and a median of -$56500.0 in 2022 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 8783.33% in 2024; the steepest drop was 13652.17% in 2024.
  • Spruce Biosciences' Change in Accured Expenses stood at -$102000.0 in 2022, then soared by 52.94% to -$48000.0 in 2023, then soared by 8783.33% to $4.2 million in 2024, then plummeted by 56.62% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Change in Accured Expenses are $1.8 million (Q4 2025), $1.1 million (Q3 2025), and -$5.0 million (Q2 2025).